Study to Assess the EffectiVeness of exIsting Anti-vascular Endothelial groWth Factor (Anti-VEGF) Treatment Regimens in Patients With Wet Age-related Macular Degeneration
- Registration Number
- NCT01933152
- Lead Sponsor
- Bayer
- Brief Summary
Retrospective, non-interventional, observational multi-center field study. Patients diagnosed with wet Age-related macular degeneration (wAMD) and having started treatment with ranibizumab between January 1, 2009 and December 31, 2009 must be consecutively screened and, if eligible, enrolled. Patients will be followed up at maximum until December 31, 2011. Switch to any other Anti vascular endothelial growth factor (anti VEGF) treatment will be documented. For each patient, demographics, medical history, administered treatments, results of ocular and visual assessments and other tests (where available) will be documented.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 137
Inclusion Criteria
- Diagnosis of wet Age-related Macular Degeneration
- Start of anti-VEGF therapy with ranibizumab (Lucentis) between January 1, 2009 and December 31, 2009
- Informed consent form signed
Exclusion Criteria
- Participation in an investigational study during anti-VEGF therapy (from start up to December 31, 2011) that involved treatment with any drug or device
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description Group 1 Ranibizumab -
- Primary Outcome Measures
Name Time Method Changes in visual acuity after start of Anti vascular endothelial growth factor (anti VEGF) therapy with ranibizumab, assessed by Early Treatment Diabetic Retinopathy (ETDRS) or Snellen chard Baseline and 24 months
- Secondary Outcome Measures
Name Time Method Mean change of visual acuity, from diagnosis to end of follow-up, assessed by Early Treatment Diabetic Retinopathy (ETDRS) or Snellen chart Baseline and 24 months Mean change of retinal thickness from diagnosis to end of follow-up, assessed by Optical Coherence Tomography (OCT) Baseline and 24 months Mean change of lesion size from diagnosis to end of follow-up, assessed by Fluorescein Angiography (FA) Baseline and 24 months Demographic characteristics of patients included in the study (Age, Sex, Race) Baseline Mean time from first clinical presentation to diagnosis Baseline Mean time from diagnosis to treatment Time from diagnosis to treatment: Up to 24 months Mean time from diagnosis to end of follow-up Time from diagnosis to end of follow-up: up to 48 months Average number of treatments given from diagnosis to end of follow-up After 24 months